BMS sources discount chance of Sanofi buyout

Dow Jones is quoting sources close to Bristol-Myers Squibb who say that a buyout by Sanofi-Aventis is not in the cards. BMS is betting on its pipeline for its future expansion, says the source. The possibility of a tie-up has caused considerable buzz in the M&A field, especially as Sanofi-Aventis has indicated its interest in snapping up a pharma and biotech company. A deal between BMS and Sanofi looked particularly compelling because it would have expanded the French company's U.S. reach while advancing relations between two companies with a long history of collaborating on drug projects. One of those projects includes the blockbuster Plavix, which was the subject of a closely watched patent lawsuit and will remain under patent protection until 2011.

- check out the CNN report

Related Articles:
Report: Sanofi-Aventis inks preliminary deal for BMS. Report
Patent victory reignites rumors of BMS takeover. Report
Rumor Mill: Is BMS going on the sales block? Report
Analysts buzzing about possible Bristol-Myers sale. Report
More details emerge on secret Plavix pact. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.